Reported cases of pertussis (also known as whooping cough) are increasing among infants and adolescents. This rise parallels the number of reported infant deaths associated with pertussis infection, which is caused by the gram-positive bacterium Bordetella pertussis. Adults are
a significant vector for transmission of pertussis to children, and people 65 years of age and older make up a substantial portion of this potential transmission pool. Evidence exists of waning immunity in the adult population after either infection or vaccination. A recommendation for the
use of a pertussis-containing vaccine (Tdap) in persons 64 years of age and older would be of considerable benefit to the public in preventing some transmission of pertussis to children. Neither of the two Tdap vaccines (pediatric or adult) is licensed for persons older than 65 years of age,
and the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention gives no off-label recommendation for use of Tdap in patients 65 years of age or older. Abbreviatioons: ACIP = Advisory Committee on Immunization Practices, CDC = Centers for
Disease Control and Prevention, DTaP = Pediatric formulation diphtheria, tetanus and acellular pertussis vaccine, GMT = Geometric Mean Titer, Td = Tetanus and diphtheria vaccine, Tdap = Adult formulation tetanus, diphtheria, and acellular pertussis vaccine.
The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.